Adlai Nortye (ADR) (ANL)
Develops clinical-stage cancer therapies targeting RAS pathways and immune responses.
Something off on this page? Send us feedback.
Develops clinical-stage cancer-therapy candidates centered on RAS-targeting therapies and next-generation cancer immunotherapies. R&D operations span China and the United States, following a shift from generics to oncology research.
Develops clinical-stage cancer-therapy candidates in two focal areas: RAS-targeting therapies and next-generation cancer immunotherapies. Its business centers on research and development rather than commercialized medicines, with the current focus following a documented transition to innovative cancer therapies.
R&D operations span China and the United States, while the listed parent was formed as a Cayman holding company for offshore financing. The operating business began in mainland China with generic pharmaceuticals and polypeptide intermediates. In 2016, the founders redirected it toward oncology-focused R&D and rebranded it as Adlai Nortye Biopharma.
The company's clinical-stage model depends on advancing cancer-therapy candidates through clinical development.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $232.8M · Total debt $26.7M · Total assets $248.4M · Shareholders' equity $214.8M
- Revenue
- $7.3M
- Operating income
- −$2.9M
- Net income
- −$2.7M
No dividends on record.
| Institutions | 49.85% | 26.46M ADS | |
|---|---|---|---|
| 42 holders · as of Jun 30, 2026 | |||
| Insiders | 11.47% | 6.09M ADS | |
| 4 holders · as of Aug 26, 2026 | |||
| Other | 38.68% | 20.53M ADS | |
| remainder | |||
53.08M ADS (1 ADS = 3 ordinary shares) as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The reported float (12.60M, 71.2% free) does not reconcile with the share count, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Yang LuInsiderdirector, 10 percent owner, officer: CEO | 10.86% | 99,990 ADS · 16.99M ordinary | filed May 21, 2026 |
Cormorant Asset Management, LPInstitution | 7.49% | 3.98M ADS | as of Jun 30, 2026 |
VR Adviser, LLCInstitution | 6.05% | 3.21M ADS | as of Jun 30, 2026 |
Balyasny Asset Management L.P.Institution | 5.77% | 3.06M ADS | as of Jun 30, 2026 |
Point72 Asset Management, L.P.Institution | 4.03% | 2.14M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Xiaofeng Ye | officer: CFO | −5,667 | $14.25 |
| Aug 24, 2026 | Xiaofeng Ye | officer: CFO | −6,000 | $13.98 |
| May 13, 2026 | Yang Lu | director, 10 percent owner, officer: CEO | −10 | $13.18 |
- Revolution Medicines
Broad RAS(ON) inhibitor pipeline for RAS-addicted cancers
- Bristol-Myers Squibb
KRAS G12C therapy and PD-1 immuno-oncology franchise
- Amgen
Commercial KRAS G12C inhibitor for lung and colorectal cancer
- Merck
PD-1 immunotherapy franchise across multiple solid tumors
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Adlai Nortye (ADR) | $16.07 | +3.19% | $826.5M | — | — | 42.0 | — |
| Revolution Medicines | $193.19 | +0.22% | $40.98B | — | — | — | — |
| Bristol-Myers Squibb | $62.79 | +0.26% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Amgen | $401.35 | +2.08% | $212.19B | 24.4 | 17.1 | 5.6 | +9.7% |
| Merck | $151.05 | +1.04% | $369.24B | 119.6 | 17.5 | 5.6 | +5.1% |
| Median | 24.4 | 17.1 | 5.6 | +5.7% |